Kathryne Van Hedger

Dr. Kathryne Van Hedger

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 December 2020 in Parkinson's Disease
Verified
Journal Article
Open access
MPMargaret T. M. Prenger
Margaret T. M. Prenger
RMRacheal Madray
Racheal Madray
KHKathryne Van Hedger
Kathryne Van Hedger
MAMimma Anello
Mimma Anello
PMPenny A. MacDonald
Penny A. MacDonald
Parkinson’s disease (PD) is typically well recognized by its characteristic motor symptoms (e.g., bradykinesia, rigidity, and tremor). The cognitive symptoms of PD are increasingly being acknowledged by clinicians and researchers alike. However, PD also involves a host of emotional and communicative changes which can cause major disruptions to social functioning. These incude problems producing emotional facial expressions (i.e., facial masking) and emotional speech (i.e., dysarthria), as well as difficulties recognizing the verbal and nonverbal emotional cues of others. These social symptoms of PD can result in severe negative social consequences, including stigma, dehumanization, and loneliness, which might affect quality of life to an even greater extent than more well-recognized motor or cognitive symptoms. It is, therefore, imperative that researchers and clinicans become aware of these potential social symptoms and their negative effects, in order to properly investigate and manage the socioemotional aspects of PD. This narrative review provides an examination of the current research surrounding some of the most common social symptoms of PD and their related social consequences and argues that proactively and adequately addressing these issues might improve disease outcomes.

31 January 2017 in Psychophysiology
Verified
Journal Article
Closed access
PDF file
KHKathryne Van Hedger
Kathryne Van Hedger
ENElizabeth A. Necka
Elizabeth A. Necka
ABAnam K. Barakzai
Anam K. Barakzai
GNGreg J. Norman
Greg J. Norman

26 April 2018 in Nicotine & Tobacco Research
Verified
Journal Article
Closed access
PDF file
KHKathryne Van Hedger
Kathryne Van Hedger
MKMeredith J Kushner
Meredith J Kushner
RLRoyce Lee
Royce Lee
HWHarriet de Wit
Harriet de Wit
Despite widespread knowledge of the dangers of cigarette consumption, smoking continues to be a public health concern. One compound that has shown potential for treatment in preclinical models is the neuropeptide oxytocin (OT). The purpose of the present study was to examine the effects of intranasal oxytocin on cigarette craving, behavioral economic demand for cigarettes, and cigarette consumption, in regular smokers after 18 hours of abstinence. Otherwise healthy daily smokers (n = 35) completed two sessions where they received OT (40 IU intranasal) or placebo (PBO) and completed measures of craving and cigarette demand, and they were given six opportunities to smoke partial cigarettes in exchange for money. On average participants smoked few cigarettes after receiving OT than after receiving PBO, and they reported less desire for additional cigarettes during the smoking period. OT did not affect cigarette demand or standardized measures of cigarette craving. This study suggests that OT decreases some indices of smoking desire and consumption, providing modest support for the idea that OT might be effective for reducing cigarette smoking. This study provides new evidence that oxytocin might have clinical value in the treatment of addictive disorders, in this case tobacco addiction. The study adds to a growing literature suggesting that this neuropeptide, which is mainly known for its role in social bonding and attachment, may also affect mood and motivational states relevant to addiction.

27 January 2020 in Nicotine & Tobacco Research
Verified
Journal Article
Closed access
PDF file
KHKathryne Van Hedger
Kathryne Van Hedger
ABAnya K Bershad
Anya K Bershad
RLRoyce Lee
Royce Lee
HWHarriet de Wit
Harriet de Wit
Cigarette smoking is a well-known public health concern, and there is an urgent need to develop new treatments to reduce smoking or facilitate abstinence. One factor that is known to contribute to relapse is stress, making the stress response an important target for treatment. The neuropeptide oxytocin (OT) is believed to have stress-reducing effects, and in addition there is evidence that it reduces drug craving. The purpose of the present study was to examine the effects of intranasal OT on stress-induced cigarette craving in regular smokers after 12 h of abstinence. Daily smokers (n = 48) completed a stress induction task and a nonstressful control task at two different sessions, receiving intranasal OT (40 IU) or placebo (PBO) before or after the task. Subjects were randomly assigned to one of three groups: Group PP (n = 16) received PBO before and after the stress/control tasks, Group OP (n = 16) received OT before the tasks and PBO after, and Group PO (n = 16) received PBO before the tasks and OT shortly after completing the tasks. Cigarette craving as well as subjective and physiological responses to stress was assessed. OT did not alter responses to stress, whether it was administered before or after the stressful task, on measures of cigarette craving, anxiety, heart rate, blood pressure, and cortisol levels. The current study findings do not support several previous reports that OT reduced either stress or drug craving. This study finds a null result of the neuropeptide oxytocin on stress-induced cigarette craving. Reporting null findings is part of the process of identifying potential treatments for addictive disorders.

20 June 2023 in Drug and Alcohol Dependence
Verified
Journal Article
Closed access
BZByron L. Zamboanga
Byron L. Zamboanga
JMJennifer E. Merrill
Jennifer E. Merrill
ANAmie R. Newins
Amie R. Newins
JOJanine V. Olthuis
Janine V. Olthuis
KHKathryne Van Hedger
Kathryne Van Hedger
DMDennis McChargue
Dennis McChargue

25 July 2020 in Preprints.org
Verified
Preprint
Open access
MPMagaret T. M. Prenger
Magaret T. M. Prenger
RMRacheal Madray
Racheal Madray
KHKathryne Van Hedger
Kathryne Van Hedger
MAMimma Anello
Mimma Anello
PMPenny A. MacDonald
Penny A. MacDonald
Parkinson’s disease (PD) is typically well-recognized by its characteristic motor symptoms (e.g., bradykinesia, rigidity, and tremor). The cognitive symptoms of PD are increasingly being acknowledged by clinicians and researchers alike. However, PD also involves a host of emotional and communicative changes which can cause major disruptions to social functioning. These include problems producing emotional facial expressions (i.e., facial masking) and emotional speech (i.e., dysarthria), as well as difficulties recognizing the verbal and non-verbal emotional cues of others. These social symptoms of PD can result in severe negative social consequences, including stigma, dehumanization, and loneliness, which might affect quality of life to an even greater extent than more well-recognized motor or cognitive symptoms. It is therefore imperative that researchers and clinicians become aware of these potential social symptoms and their negative effects, in order to properly investigate and manage the socioemotional aspects of PD. The present review provides an examination of the current research surrounding some of the most common social symptoms of PD and their related social consequences, and argues that proactively and adequately addressing these issues might improve disease outcomes.